Iaina A - Search Results

1

Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects.

Grosskopf I, Ringel Y, Charach G, Maharshak N, Mor R, Iaina A, Weintraub M. Grosskopf I, et al. Among authors: iaina a. Diabetes Care. 1997 Oct;20(10):1598-602. doi: 10.2337/diacare.20.10.1598. Diabetes Care. 1997. PMID: 9314642 Clinical Trial.

2

Postprandial intestinal-derived chylomicron and chylomicron remnants in essential hypertensive patients before and after prolonged captopril therapy.

Iaina A, Silverberg DS, Wollman Y, Judevics R, Baruch R, Levhar C, Peer G, Blum M, Grosskopf I, Weintraub MS. Iaina A, et al. Am J Hypertens. 1995 Jan;8(1):34-9. doi: 10.1016/0895-7061(94)00188-H. Am J Hypertens. 1995. PMID: 7734094

3

Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.

Weintraub M, Rassin T, Eisenberg S, Ringel Y, Grosskopf I, Iaina A, Charach G, Liron M, Rubinstein A. Weintraub M, et al. Among authors: iaina a. J Lipid Res. 1994 Feb;35(2):229-38. J Lipid Res. 1994. PMID: 8169526 Free article.

4

Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years.

Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, Liron M, Rubinstein A, Iaina A. Weintraub MS, et al. Among authors: iaina a. BMJ. 1996 Apr 13;312(7036):935-9. doi: 10.1136/bmj.312.7036.935. BMJ. 1996. PMID: 8616304 Free PMC article.

5

Bezafibrate therapy in patients with isolated low high-density lipoprotein cholesterol levels may have a beneficial effect in prevention of atherosclerosis.

Weintraub MS, Grosskopf I, Charach G, Mor R, Rubinstein A, Wollman Y, Judevices R, Iaina A. Weintraub MS, et al. Among authors: iaina a. Metabolism. 1995 Nov;44(11):1401-9. doi: 10.1016/0026-0495(95)90137-x. Metabolism. 1995. PMID: 7476325 Clinical Trial.

6

Severe defect in clearing postprandial chylomicron remnants in dialysis patients.

Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S, Blum M, Peer G, Iaina A. Weintraub M, et al. Among authors: iaina a. Kidney Int. 1992 Nov;42(5):1247-52. doi: 10.1038/ki.1992.411. Kidney Int. 1992. PMID: 1453610 Free article.

7

Low nitric oxide production in patients with chronic renal failure.

Blum M, Yachnin T, Wollman Y, Chernihovsky T, Peer G, Grosskopf I, Kaplan E, Silverberg D, Cabili S, Iaina A. Blum M, et al. Among authors: iaina a. Nephron. 1998;79(3):265-8. doi: 10.1159/000045047. Nephron. 1998. PMID: 9678424

8

Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension.

Peer G, Itzhakov E, Wollman Y, Chernihovsky T, Grosskopf I, Segev D, Silverberg D, Blum M, Schwartz D, Iaina A. Peer G, et al. Among authors: iaina a. Nephrol Dial Transplant. 2001 Jul;16(7):1436-41. doi: 10.1093/ndt/16.7.1436. Nephrol Dial Transplant. 2001. PMID: 11427637 Clinical Trial.

9

Role of nitric oxide (EDRF) in radiocontrast acute renal failure in rats.

Schwartz D, Blum M, Peer G, Wollman Y, Maree A, Serban I, Grosskopf I, Cabili S, Levo Y, Iaina A. Schwartz D, et al. Among authors: iaina a. Am J Physiol. 1994 Sep;267(3 Pt 2):F374-9. doi: 10.1152/ajprenal.1994.267.3.F374. Am J Physiol. 1994. PMID: 8092251

10

Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril.

Schwartz D, Kornowski R, Schwartz IF, Dotan I, Weinreb B, Averbuch M, Golan Y, Levo Y, Iaina A. Schwartz D, et al. Among authors: iaina a. Cardiovasc Drugs Ther. 1996 Mar;10(1):75-9. doi: 10.1007/BF00051133. Cardiovasc Drugs Ther. 1996. PMID: 8723173 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters